Clinicopathological characteristics and prognosis of 77 cases with type 3 gastric neuroendocrine tumours

doi:10.4251/wjgo.v12.i12.1416

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 12, Issue 12

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (7334)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series, Tables (1-4) series.

Item

Count

PDF

228

WORD

197

HTML

2396

Figures (1-1)

300

Tables (1-4)

279

Sum=3400

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

345

Download

1063

Sum=1408

Publishing Process of This Article

Item

Count

Browse

697

Download

1829

Sum=2526

Dec 15, 2020 (publication date) through Jan 12, 2025

Times Cited of This Article

Times Cited (14)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Gastrointest Oncol. Dec 15, 2020; 12(12): 1416-1427
Published online Dec 15, 2020. doi: 10.4251/wjgo.v12.i12.1416

Table 1 Clinicopathological features of type 3 gastric neuroendocrine tumours

	Total, n (%)	G1 NETs, n (%)	G2 NETs, n (%)	G3 NETs, n (%)	P value	G2 vs G1	G3 vs G1	G3 vs G2
Number	77 (100)	37 (48.1)	31 (40.3)	9 (11.7)
Age (range)	48 (28-79)	47 (29-79)	47.5 (28-78)	62 (33-68)	0.048	1	0.077	0.049
Gender					0.016	1.000	0.011	0.039
Male	34 (44.2)	13 (35.1)	13 (41.9)	8 (88.9)
Female	43 (55.8)	24 (64.9)	18 (58.1)	1 (11.1)
Size (cm)	1.5 (0.8-3.5)	0.8 (0.5-1.2)	3 (1.5-5)	4 (2.5-5.25)	< 0.001	< 0.001	< 0.001	1.000
Site					0.122
Cardia	10 (13)	2 (5.4)	6 (19.4)	2 (22.2)
Fundus/body	64 (83.1)	34 (91.9)	24 (77.4)	6 (66.7)
Antrum	3 (3.9)	1 (2.7)	1 (3.2)	1 (11.1)
Number					0.087
1	64 (83.1)	27 (73)	28 (90.3)	9 (100)
≥ 2	13 (16.9)	10 (27)	3 (9.7)	0
EA					0.002	0.001	0.055	1.000
Polyp	45 (61.6)	29 (82.9)	12 (41.4)	4 (44.4)
Bulge	11 (15.1)	4 (11.4)	6 (20.7)	1 (11.1)
Ulcer	17 (23.3)	2 (5.7)	11 (37.9)	4 (44.4)
Unknown	4	2	2	0
Infiltration					0.014	0.014	0.290	1.000
M/SM	22 (64.7)	17 (85.0)	4 (36.4)	1 (33.3)
MP	5 (14.7)	2 (10)	2 (18.2)	1 (33.3)
Beyond MP	7 (20.6)	1 (5.0)	5 (45.5)	1 (33.3)
Unknown	43	17	20	6
Ki67 (%)	3 (1-10)	1 (1-1)	8 (4-10)	30 (25-37.5)	< 0.001	< 0.001	< 0.001	0.047
LNM only	10 (13.0)	2 (5.4)	7 (22.6)	1 (11.1)	< 0.001	0.027	0.439	1.000
DM	24 (31.2)	2 (5.4)	15 (48.4)	7 (77.7)	< 0.001	< 0.001	< 0.001	0.288
Stage					< 0.001	< 0.001	< 0.001	0.494
I	30 (39.0)	26 (70.3)	4 (12.9)	0
II	12 (15.6)	7 (18.9)	5 (16.1)	0
III	11 (14.3)	2 (5.4)	7 (22.6)	2 (22.2)
IV	24 (31.2)	2 (5.4)	15 (48.4)	7 (77.8)
Treatment					< 0.001	< 0.001	< 0.001	0.510
ER	33 (42.9)	29 (78.4)	4 (12.9)	0
Surgery	17 (22.1)	5 (13.5)	10 (32.3)	2 (22.2)
SSA	6 (7.8)	1 (2.7)	4 (12.9)	1 (11.1)
CBCT	21 (27.3)	2 (5.4)	13 (41.9)	6 (66.7)

NET: Neuroendocrine tumour; SD: Standard deviation; EA: Endoscopic appearance; M: Mucosa; SM: Submucosa; MP: Muscularis propria; ER: Endoscopic resection; LNM: Lymph node metastasis; DM: Distant metastasis; SSA: Somatostatin analogs; CBCT: Chemotherapy-based comprehensive treatment.

Citation: Li YL, Qiu XD, Chen J, Zhang Y, Li J, Xu JM, Wang C, Qi ZR, Luo J, Tan HY. Clinicopathological characteristics and prognosis of 77 cases with type 3 gastric neuroendocrine tumours. World J Gastrointest Oncol 2020; 12(12): 1416-1427
URL: https://www.wjgnet.com/1948-5204/full/v12/i12/1416.htm
DOI: https://dx.doi.org/10.4251/wjgo.v12.i12.1416